San Diego, California — According to state and local economic development sources Acadia Pharmaceuticals plans to invest $5,130,244.00 to build out 59,654 square feet of new space in San Diego. The company plans to occupy the new space at 12830 El Camino Real in San Diego, on or about December 1, 2020. According to the company website ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA’s product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.

To learn more about Acadia Pharmaceuticals, visit http://www.acadia-pharm.com/

Company Contact:
Stephen Davis, Chief Executive Officer
https://www.linkedin.com/in/steve-davis-74b86910/
858-558-2871

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved